Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
HILL CHARLES HExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 18,876 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001225208-13-006461 · doc4.xml · derivative · entry 7 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,876 shares Expires 2013-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Dividend equivalents are paid on these stock appreciation rights at the time of settlement. F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
HILL CHARLES HExecutive Vice President
|
Tax withholdingCommon Stock | 18,871 | $27.37 | $516,499.27 |
DisclosureSEC source: 0001225208-13-006461 · doc4.xml · nonDerivative · entry 5 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,185 F5 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations and payment of exercise price in connection with the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
HILL CHARLES HExecutive Vice President
|
Tax withholdingCommon Stock | 3,708 | $27.37 | $101,487.96 |
DisclosureSEC source: 0001225208-13-006461 · doc4.xml · nonDerivative · entry 4 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,056 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
HILL CHARLES HExecutive Vice President
|
GrantCommon Stock | 9,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006461 · doc4.xml · nonDerivative · entry 3 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,764 F3 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
HILL CHARLES HExecutive Vice President
|
GrantCommon Stock | 17,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006461 · doc4.xml · nonDerivative · entry 2 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,049 F2 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
HILL CHARLES HExecutive Vice President
|
Exercise / conversionCommon Stock | 21,924 | $22.55 | $494,386.20 |
DisclosureSEC source: 0001225208-13-006461 · doc4.xml · nonDerivative · entry 1 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:26 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 86,837 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006466 · doc4.xml · derivative · entry 6 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,837 Underlying: Common Stock · 86,837 shares Expires 2020-02-28 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:26 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 104,626 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006466 · doc4.xml · derivative · entry 5 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,626 Underlying: Common Stock · 104,626 shares Expires 2018-02-28 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:26 UTC |
Lewis-Hall Freda CExecutive Vice President
|
Tax withholdingCommon Stock | 24,403 | $27.37 | $667,910.11 |
DisclosureSEC source: 0001225208-13-006466 · doc4.xml · nonDerivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,499 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:26 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantCommon Stock | 17,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006466 · doc4.xml · nonDerivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,902 F2 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:26 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantCommon Stock | 43,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006466 · doc4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,205 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 38,848 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006462 · doc4.xml · derivative · entry 9 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,848 Underlying: Common Stock · 38,848 shares Expires 2020-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 46,806 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006462 · doc4.xml · derivative · entry 8 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,806 Underlying: Common Stock · 46,806 shares Expires 2018-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 12,200 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001225208-13-006462 · doc4.xml · derivative · entry 7 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,200 shares Expires 2013-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Dividend equivalents are paid on these stock appreciation rights at the time of settlement. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 12,197 | $27.37 | $333,831.89 |
DisclosureSEC source: 0001225208-13-006462 · doc4.xml · nonDerivative · entry 5 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,523 F5 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations and payment of exercise price in connection with the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 5,403 | $27.37 | $147,880.11 |
DisclosureSEC source: 0001225208-13-006462 · doc4.xml · nonDerivative · entry 4 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,720 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantCommon Stock | 7,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006462 · doc4.xml · nonDerivative · entry 3 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,123 F3 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionCommon Stock | 14,170 | $22.55 | $319,533.50 |
DisclosureSEC source: 0001225208-13-006462 · doc4.xml · nonDerivative · entry 2 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:22 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantCommon Stock | 14,171 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006462 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,036 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
MADDALUNA ANTHONY JExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 61,700 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006474 · doc4.xml · derivative · entry 9 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,700 Underlying: Common Stock · 61,700 shares Expires 2020-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
MADDALUNA ANTHONY JExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 74,339 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006474 · doc4.xml · derivative · entry 8 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,339 Underlying: Common Stock · 74,339 shares Expires 2018-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
MADDALUNA ANTHONY JExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 17,140 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001225208-13-006474 · doc4.xml · derivative · entry 7 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,140 shares Expires 2013-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Dividend equivalents are paid on these stock appreciation rights at the time of settlement. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
MADDALUNA ANTHONY JExecutive Vice President
|
Tax withholdingCommon Stock | 16,465 | $27.37 | $450,647.05 |
DisclosureSEC source: 0001225208-13-006474 · doc4.xml · nonDerivative · entry 5 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,424 F5 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations and payment of exercise price in connection with the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
MADDALUNA ANTHONY JExecutive Vice President
|
Tax withholdingCommon Stock | 3,772 | $27.37 | $103,239.64 |
DisclosureSEC source: 0001225208-13-006474 · doc4.xml · nonDerivative · entry 4 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,889 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
MADDALUNA ANTHONY JExecutive Vice President
|
GrantCommon Stock | 10,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006474 · doc4.xml · nonDerivative · entry 3 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,661 F3 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
MADDALUNA ANTHONY JExecutive Vice President
|
GrantCommon Stock | 12,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006474 · doc4.xml · nonDerivative · entry 2 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,459 F2 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
MADDALUNA ANTHONY JExecutive Vice President
|
Exercise / conversionCommon Stock | 19,908 | $22.55 | $448,925.40 |
DisclosureSEC source: 0001225208-13-006474 · doc4.xml · nonDerivative · entry 1 MADDALUNA ANTHONY J · CIK 0001566333 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
OLSON LAURIE JExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 31,993 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · derivative · entry 9 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,993 Underlying: Common Stock · 31,993 shares Expires 2020-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
OLSON LAURIE JExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 38,546 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · derivative · entry 8 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,546 Underlying: Common Stock · 38,546 shares Expires 2018-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
OLSON LAURIE JExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 11,510 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · derivative · entry 7 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,510 shares Expires 2013-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Dividend equivalents are paid on these stock appreciation rights at the time of settlement. F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
OLSON LAURIE JExecutive Vice President
|
Tax withholdingCommon Stock | 10,946 | $27.37 | $299,592.02 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · nonDerivative · entry 5 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,347 F5 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations and payment of exercise price in connection with the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
OLSON LAURIE JExecutive Vice President
|
Tax withholdingCommon Stock | 3,367 | $27.37 | $92,154.79 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · nonDerivative · entry 4 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,293 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
OLSON LAURIE JExecutive Vice President
|
GrantCommon Stock | 6,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · nonDerivative · entry 3 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,660 F3 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
OLSON LAURIE JExecutive Vice President
|
GrantCommon Stock | 9,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,140 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:36 UTC |
OLSON LAURIE JExecutive Vice President
|
Exercise / conversionCommon Stock | 13,368 | $22.55 | $301,448.40 |
DisclosureSEC source: 0001225208-13-006475 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:44 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 539,305 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006477 · doc4.xml · derivative · entry 11 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,305 Underlying: Common Stock · 539,305 shares Expires 2020-02-28 F11 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F11 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:44 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 649,780 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006477 · doc4.xml · derivative · entry 10 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,780 Underlying: Common Stock · 649,780 shares Expires 2018-02-28 F10 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F10 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:44 UTC |
READ IAN CDirector · Chairman & CEO
|
Exercise / conversionStock Appreciation Rights · Derivative | 168,739 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001225208-13-006477 · doc4.xml · derivative · entry 9 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 168,739 shares Expires 2013-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · shares: Dividend equivalents are paid on these stock appreciation rights at the time of settlement. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:44 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantPhantom Stock Units SSP · Derivative | 136 | $27.37 | $3,722.32 |
DisclosureSEC source: 0001225208-13-006477 · doc4.xml · derivative · entry 8 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,006 Underlying: Common Stock · 136 shares Expires not disclosed F7 · derivative.exercise_price: Each unit represents one phantom share of common stock. F8 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F8 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:44 UTC |
READ IAN CDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 168,120 | $27.37 | $4,601,444.40 |
DisclosureSEC source: 0001225208-13-006477 · doc4.xml · nonDerivative · entry 5 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,123,696 F5 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations and payment of exercise price in connection with the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:44 UTC |
READ IAN CDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 42,969 | $27.37 | $1,176,061.53 |
DisclosureSEC source: 0001225208-13-006477 · doc4.xml · nonDerivative · entry 4 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,291,816 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:44 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantCommon Stock | 85,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006477 · doc4.xml · nonDerivative · entry 3 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,334,785 F3 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:44 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantCommon Stock | 109,911 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006477 · doc4.xml · nonDerivative · entry 2 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,249,780 F2 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:44 UTC |
READ IAN CDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 195,985 | $22.55 | $4,419,461.75 |
DisclosureSEC source: 0001225208-13-006477 · doc4.xml · nonDerivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,139,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:53 UTC |
SCHULMAN AMY WExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 137,112 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006479 · doc4.xml · derivative · entry 7 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,112 Underlying: Common Stock · 137,112 shares Expires 2020-02-28 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:53 UTC |
SCHULMAN AMY WExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 165,198 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006479 · doc4.xml · derivative · entry 6 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,198 Underlying: Common Stock · 165,198 shares Expires 2018-02-28 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:53 UTC |
SCHULMAN AMY WExecutive Vice President
|
Tax withholdingCommon Stock | 20,336 | $27.37 | $556,596.32 |
DisclosureSEC source: 0001225208-13-006479 · doc4.xml · nonDerivative · entry 3 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,167 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:53 UTC |
SCHULMAN AMY WExecutive Vice President
|
GrantCommon Stock | 27,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006479 · doc4.xml · nonDerivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,503 F2 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 00:53 UTC |
SCHULMAN AMY WExecutive Vice President
|
GrantCommon Stock | 36,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-006479 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,560 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2013 Filed Mar 5, 2013 01:00 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 91,408 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-13-006487 · doc4.xml · derivative · entry 9 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,408 Underlying: Common Stock · 91,408 shares Expires 2020-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.